Alaunos Therapeutics (FRA:WEK) ROCE % : -293.30% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Alaunos Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alaunos Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -293.30%.

Alaunos Therapeutics ROCE % Historical Data

The historical data trend for Alaunos Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics ROCE % Chart

Alaunos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-64.23

-68.43

-78.47

-60.31

-137.62

Alaunos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-85.21	-101.07	-112.43	-181.80	-293.30

Alaunos Therapeutics ROCE % Calculation

Alaunos Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-30.462	/	( ( (61.301 - 22.813)	+	(7.577 - 1.794) )	/ 2 )
	=	-30.462	/	( (38.488	+	5.783)	/ 2 )
	=	-30.462	/	22.1355
	=	-137.62 %

Alaunos Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-28.768	/	( ( (18.215 - 4.381)	+	(7.577 - 1.794) )	/ 2 )
	=	-28.768	/	( ( 13.834	+	5.783 )	/ 2 )
	=	-28.768	/	9.8085
	=	-293.30 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Alaunos Therapeutics (FRA:WEK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alaunos Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alaunos Therapeutics (FRA:WEK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (FRA:WEK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TCRT:USA

Address

8030 El Rio Street, Houston, TX, USA, 77054

Website

https://www.alaunos.com

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Alaunos Therapeutics (FRA:WEK) Headlines

No Headlines